Category Archives: Covid-19/2019-nCoV

The early days of a campus COVID-19 response: pivot and pivot again

By on .

By Lisa V. Adams, MD, and Kavita Kantamneni, MPH When Lisa describes her early days on Dartmouth’s COVID-19 response, she asks people to recall their “first COVID-19 moment,” that instant when they realized this was not a drill, that this was going to be something big and life-altering. For her, that was on Jan. 31, […]

Comments on key documents from the early weeks of SARS-CoV-2

By on .

By Daniel R. Lucey MD, MPH, FIDSA The purpose of this blog is to provide comments on reporting of some of the key COVID-19 events from 23 Chinese publications dated Dec. 31, 2019, until Feb. 17, 2021. Except for the five from the China CDC Weekly website, most are no longer online; however, I saved […]

Heightened vigilance needed to solve persisting enigma of melioidosis cases in Kansas, Minnesota and Texas

By on .

By Daniel R. Lucey MD, MPH, FIDSA On June 30, 2021, CDC issued a Health Advisory via its Health Alert Network stating: “The Kansas Department of Health and Environment, the Texas Department of State Health Services, and the Minnesota Department of Health, with assistance from the Centers for Disease Control and Prevention (CDC), are investigating […]

Clues to COVID origins via Wuhan wet market study 2017-2019 of severe fever with thrombocytopenia syndrome

By on .

By Daniel R. Lucey MD, MPH, FIDSA Retrospective testing for SARS-CoV-2 virus and antibody could be (or has been) done using blood and other samples highly likely to have been obtained from the 18 mammalian species (including masked palm civet, racoon dogs, and mink) reported in the Wuhan wet markets, May 2017-November 2019, as part […]

Not until June 2021 does China report Wuhan wet markets sold palm civets, racoon dogs and mink from 2017-2019: Where are the SARS-CoV-2 results?

By on .

By Daniel R. Lucey MD, MPH, FIDSA Last month a paper titled “Animal sales from Wuhan wet markets immediately prior to the COVID-19 pandemic” by Xiao et al., in Nature Scientific Reports listed 18 mammalian species sold May 2017 -November 2019 in Wuhan wet markets (Table 1).  These mammalian species included masked palm civets (Paguma […]

Why has no Gamma variant (P.1) been reported in Africa despite being found in 72 nations in the Americas, Asia, Europe and Australia? 

By on .

By Daniel R. Lucey MD, MPH, FIDSA Every week the World Health Organization posts an epidemiological update that includes global maps (below) and nation-by-nation listing in Annex 1 (below) for each of their four variants of concern: Alpha, Beta, Gamma, and Delta.  Multiple nations in Africa have reported Alpha, Beta, and Delta variants. In contrast, no […]

WHO designates “Lambda” as global variant of interest

By on .

By Daniel R. Lucey MD, MPH, FIDSA In its weekly COVID-19 epidemiology update this week the World Health Organization stated that the “Lambda” was designated a variant of interest “based upon evidence of continued emergence and suspected phenotypic implications” (boldtype below was added). “Authorities in Peru reported that 81% of COVID-19 cases sequenced since April 2021 […]

HHS cites increasing rate of variants P.1 and B.351 in recommending use of Regeneron (but no longer Lilly) monoclonal antibody combination in eight states

By on .

By Daniel R. Lucey MD, MPH, FIDSA On Wednesday (May 26) the Department of Health and Human Services made the clinically-relevant important update below.  (I anticipate more than these eight states to be included in the weeks and months ahead as the variants P.1. and B.1. 351 continue to spread in the United States). ​“Important […]

As substance use disorders rise in the midst of a pandemic, a new law is needed now to facilitate treatment

By on .

While America’s epidemic of opioid use was already a burgeoning health crisis, it has worsened markedly since the onset of the COVID-19 pandemic. Between September 2019 and September 2020, the U.S. Centers for Disease Control and Prevention estimates, deaths caused by opioid overdoses have increased by nearly a third. Dr. Ellen Eaton, of the Outpatient-Based […]

Will the China report on 266 patients Nov. 17-Dec. 31, 2019 be made public by China, WHO, or by WHA resolution next week?

By on .

By Daniel R. Lucey MD, MPH, FIDSA In a recent Science paper by Pekar, Worobey and colleagues titled “Timing the SARS-CoV-2 index case in Hubei province” the authors conclude “Our results define the period between mid-October and mid-November 2019 as the plausible interval when the first case of SARS-CoV-2 emerged in Hubei province.” Referencing reporting […]